### Yazar "Buyukgebiz, B" seçeneğine göre listele

Listeleniyor 1 - 6 / 6

###### Sayfa Başına Sonuç

###### Sıralama seçenekleri

Öğe Current therapeutic approaches in childhood chronic hepatitis B infection(Elsevier Science Bv, 2003) Dikici, B; Ozgenec, F; Kalayci, A; Targan, S; Ozkan, T; Selimoglu, A; Doganci, T; Kansu, A; Tosun, S; Arslan, N; Kasirga, E; Bosnak, M; Ece, A; Buyukgebiz, B; Aydogdu, S; Girgin, N; Yagci, RVDaha fazla Öğe Current therapeutic approaches in childhood chronic hepatitis B infection(Elsevier Science Bv, 2003) Dikici, B; Ozgenec, F; Kalayci, A; Targan, S; Ozkan, T; Selimoglu, A; Doganci, T; Kansu, A; Tosun, S; Arslan, N; Kasirga, E; Bosnak, M; Ece, A; Buyukgebiz, B; Aydogdu, S; Girgin, N; Yagci, RVDaha fazla Öğe Current therapeutic approaches in childhood chronic hepatitis B infection: A multicenter study(Blackwell Publishing Asia, 2004) Dikici, B; Ozgenc, F; Kalayci, AG; Targan, S; Ozkan, T; Selimoglu, A; Doganci, T; Kansu, A; Tosun, S; Arslan, N; Kasirga, E; Bosnak, M; Haspolat, K; Buyukgebiz, B; Aydogdu, S; Girgin, N; Yagci, RVDaha fazla Background and Aim: The aim of the present study was to compare the therapeutic efficacy of three different regimens in childhood chronic hepatitis B (CHB) infection. Methods: A total of 182 children with CHB infection were prospectively allocated to three random groups. Sixty-two patients in the first group received high-dose interferon (IFN)-alpha 2b (10 MU/m(2)) thrice/weekly alone for 6 months. In the second (n = 60) and third groups (n = 60), IFN-alpha was used for 6 months (5 MU/m(2)) thrice/weekly in combination with lamivudine (LAM) (4 mg/kg, maximum 100 mg/day) for 12 months. Lamivudine was started simultaneously with IFN in the second group, while it was started 2 months prior to IFN injections in the third group. Results: The initial mean alanine aminotransferase (ALT) values for the first, second and third groups were 109 +/- 93 IU/L, 101 +/- 64 IU/L and 92 +/- 42 IU/L, respectively (P > 0.05). At the end of the therapy, ALT values decreased to 82 +/- 111 IU/L, 38 +/- 41 IU/L and 29 +/- 16 IU/L in groups 1, 2 and 3, respectively. The mean ALT value of the first group was significantly different to the second and third groups (P = 0.046 and P = 0.002, respectively) at the end of the therapy and these differences were found to be sustained after 18 months. However, results in the second and third groups were similar (P > 0.05). There were no significant differences in HBeAg clearance and anti-HBe seroconversion at the initial stage, 12 months and 18 months between the three groups (P > 0.05). Hepatitis B virus (HBV) DNA clearance in the first group was different from the second and third groups, while the second and third groups had similar HBV DNA clearance ratios at 12 and 18 months. No significant difference was found in the complete response (normalization of ALT, clearance of HBV DNA and seroconversion of anti HBe) ratios of all groups (at 12 months: 28.8, 45.5, 35.8% and at 18 months 33.3, 49 and 34% in groups 1, 2 and 3, respectively, P > 0.05). Conclusions: Although the ALT normalization and HBV DNA clearance ratios of IFN plus LAM combination groups were better than the high-dose IFN-alpha monotherapy group, no significant difference was found in the complete response ratios of all three groups. (C) 2004 Blackwell Publishing Asia Pty Ltd.Daha fazla Öğe A marked difference between two population under mass screening of neonatal hTSH and biotinidase activity.(Amer Assoc Clinical Chemistry, 2002) Tanyalcin, T; Eyskens, F; Philips, E; Lefevere, M; Buyukgebiz, BDaha fazla Öğe A marked difference between two populations under mass screening of neonatal TSH and biotinidase activity(Springer-Verlag, 2002) Tanyalcin, T; Eyskens, F; Philips, E; Lefevere, M; Buyukgebiz, BDaha fazla Health-associated reference values are universally needed in clinical chemistry. The aim of this study was to establish the reference intervals of two populations from data obtained by the mass screening of newborn babies and to demonstrate how to determine 95% confidence intervals around the lower and upper limits of reference values from values that are not normally distributed. Biotinidase activities from Belgian (n=260) and Turkish (n=328) populations were measured by fluorometric assay and expressed as 1 IU (1 nmol/(dl min). Neonatal thyroid-stimulating hormone (nTSH) values from Belgian (n=4186) and Turkish (n=1663) populations were also measured by the solid phase two-site fluoroimmunometric assay, the results were given as muU/ml blood. Transformation of data was performed for each parameter. A parametric method was used for determination of reference values of biotinidase activity and the Belgian population was significantly higher than the Turkish population. nTSH reference values were evaluated by an exact non-parametric method, but approximate calculation based on the central limit theorem was also performed for confidence intervals around the reference limits. nTSH values of the Turkish population were found to be significantly higher than for the Belgian population. Rank numbers were found by an exact non-parametric method based upon the assumption of a binomial distribution. This study shows a procedure to define the rank numbers for n>1000 and to obtain reference values with 95% confidence intervals for lower and upper reference limits.Daha fazla Öğe Reference values of galactose 1 phosphate in Turkish neonates.(Amer Assoc Clinical Chemistry, 2002) Tanyalcin, T; Lefevere, M; Eyskens, F; Buyukgebiz, BDaha fazla